Area of research
Atomic and Molecular Physics, and Optics · Electrical and Electronic Engineering
Research interest
Research focused on Substantia nigra and Neuroprotection, with related work in Photothermal therapy, Endocrinology, Pars compacta. Notable publications include 'Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer's disease', 'Neuroprotective effects of a GIP analogue in the MPTP Parkinson's disease mouse model', and 'The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson’s Disease'.
Nanocarrier-based drug delivery system with dual targeting and NIR/pH response for synergistic treatment of oral squamous cell carcinoma
A Graphene-Based Lipid Modulation Nanoplatform for Synergetic Lipid Starvation/Chemo/Photothermal Therapy of Oral Squamous Cell Carcinoma
Transparent injectable sericin-honey hydrogel with antioxidant and antibacterial activities combined with feeding sericin accelerates diabetic wound healing
Lactococcus garvieae as a Novel Pathogen in Cultured Pufferfish (Takifugu obscurus) in China
Nano-drug delivery system targeting FAP for the combined treatment of oral leukoplakia
The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson’s Disease
Outbreak of a novel disease associated with Citrobacter freundii infection in freshwater cultured stingray, Potamotrygon motoro
Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer's disease
Identification and expression analysis of three XCR1-like receptors from Epinephelus coioides after Cryptocaryon irritans infection
D-Ala2-GIP-glu-PAL is neuroprotective in a chronic Parkinson's disease mouse model and increases BNDF expression while reducing neuroinflammation and lipid peroxidation
Therapeutic Potential of Genipin in Central Neurodegenerative Diseases
Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases
Neuroprotective effects of a GIP analogue in the MPTP Parkinson's disease mouse model
Neuroprotective effects of an oxyntomodulin analogue in the MPTP mouse model of Parkinson's disease